Effect of a History of Major Depressive Disorder on Smoking-induced Dopamine Release

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2009 Jul 31

PMID 19640507

Citations 21

Authors

Arthur L Brody

Richard E Olmstead

Anna L Abrams

Matthew R Costello

Aliyah Khan

Daniel Kozman

Sanjaya Saxena

Judah Farahi

Edythe D London

Mark A Mandelkern

Affiliations

Soon will be listed here.

Abstract

Background: Dopamine (DA) system dysfunction is implicated in the pathophysiology of major depressive disorder (MDD). We sought to determine if cigarette smokers with a history of MDD and current mild depressive symptoms have abnormal smoking-induced DA release (measured indirectly as change in (11)C-raclopride binding potential [BP(ND)]).

Methods: Fifty-six cigarette smokers either with (n = 10) or without (n = 46) a history of MDD (MDD+ and MDD-, respectively) underwent bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography, during which they smoked a regular cigarette. Presmoking to postsmoking changes in (11)C-raclopride BP(ND) were compared between groups. Also, correlations were determined between change in BP(ND) and depression, anxiety, and withdrawal rating scale scores for the MDD+ group.

Results: The MDD+ group had a significantly greater reduction in (11)C-raclopride BP(ND) (-16.3%) than the MDD- group (-8.4%) (analysis of covariance [ANCOVA], p = .03). Significant negative correlations were found between depression/anxiety and change in (11)C-raclopride BP(ND) (r = -.77, p < .01 and r = -.74, p = .01, respectively).

Conclusions: MDD+ smokers have greater smoking-induced DA release than MDD- smokers, and higher depression/anxiety levels are associated with greater smoking-induced DA release. These findings support the theory that MDD+ smokers have DA system dysfunction, including heightened smoking-induced DA release.

Citing Articles

Factors Influencing Knowledge and Attitudes towards Second-Hand Smoking Exposure Among University Students: An Exploratory Study.

Islam M, Al-Mamun F, ALmerab M, Moonajilin M, Mamun M Inquiry. 2025; 62:469580251314783.

PMID: 39865647 PMC: 11770711. DOI: 10.1177/00469580251314783.

Tobacco Smoke Exposure in Children and Adolescents: Prevalence, Risk Factors and Co-Morbid Neuropsychiatric Conditions in a US Nationwide Study.

Salehi M, Saeidi M, Kasulis N, Barias T, Kainth T, Gunturu S Healthcare (Basel). 2024; 12(21).

PMID: 39517315 PMC: 11545687. DOI: 10.3390/healthcare12212102.

The interacting effects of depression symptoms and sweet flavoring on the rewarding and reinforcing value of cigarillo use among young adults.

Audrain-McGovern J, Klapec O, Koita F, Manikandan D, Stone M Drug Alcohol Depend Rep. 2024; 11:100234.

PMID: 38646014 PMC: 11033167. DOI: 10.1016/j.dadr.2024.100234.

Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies.

Mizuno Y, Ashok A, Bhat B, Jauhar S, Howes O J Psychopharmacol. 2023; 37(11):1058-1069.

PMID: 37811803 PMC: 10647912. DOI: 10.1177/02698811231200881.

Impact of tobacco and/or nicotine products on health and functioning: a scoping review and findings from the preparatory phase of the development of a new self-report measure.

Afolalu E, Spies E, Bacso A, Clerc E, Abetz-Webb L, Gallot S Harm Reduct J. 2021; 18(1):79.

PMID: 34330294 PMC: 8325199. DOI: 10.1186/s12954-021-00526-z.

References

Parsey R, Oquendo M, Zea-Ponce Y, Rodenhiser J, Kegeles L, Pratap M . Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001; 50(5):313-22. DOI: 10.1016/s0006-3223(01)01089-7. View

Montgomery A, Lingford-Hughes A, Egerton A, Nutt D, Grasby P . The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse. 2007; 61(8):637-45. DOI: 10.1002/syn.20419. View

Meyer J, McNeely H, Sagrati S, Boovariwala A, Martin K, Verhoeff N . Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006; 163(9):1594-602. DOI: 10.1176/ajp.2006.163.9.1594. View

Dhaenen H, Bossuyt A . Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994; 35(2):128-32. DOI: 10.1016/0006-3223(94)91202-5. View

Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni M . Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res. 2006; 147(2-3):243-8. DOI: 10.1016/j.pscychresns.2006.03.001. View

Shah P, Ogilvie A, Goodwin G, Ebmeier K . Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med. 1997; 27(6):1247-56. DOI: 10.1017/s0033291797005382. View

Agrawal A, Sartor C, Pergadia M, Huizink A, Lynskey M . Correlates of smoking cessation in a nationally representative sample of U.S. adults. Addict Behav. 2008; 33(9):1223-6. PMC: 2516971. DOI: 10.1016/j.addbeh.2008.04.003. View

Meyer J, Kruger S, Wilson A, Christensen B, Goulding V, Schaffer A . Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001; 12(18):4121-5. DOI: 10.1097/00001756-200112210-00052. View

Brody A, Mandelkern M, Olmstead R, Scheibal D, Hahn E, Shiraga S . Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry. 2006; 63(7):808-16. PMC: 2873693. DOI: 10.1001/archpsyc.63.7.808. View

10.

Park M, Park E . Synaptic concentration of dopamine in rat striatal slices in relationship to [3H]raclopride binding to the dopamine D2 receptor. Arch Pharm Res. 2000; 23(4):360-6. DOI: 10.1007/BF02975448. View

11.

Meyer J, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A . Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006; 63(11):1209-16. DOI: 10.1001/archpsyc.63.11.1209. View

12.

Tremblay L, Naranjo C, Cardenas L, Herrmann N, Busto U . Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry. 2002; 59(5):409-16. DOI: 10.1001/archpsyc.59.5.409. View

13.

Berlin I, Covey L . Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006; 101(12):1814-21. DOI: 10.1111/j.1360-0443.2006.01616.x. View

14.

Bilder R, Volavka J, Lachman H, Grace A . The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004; 29(11):1943-61. DOI: 10.1038/sj.npp.1300542. View

15.

Carson R, Breier A, de Bartolomeis A, Saunders R, Su T, Schmall B . Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab. 1997; 17(4):437-47. DOI: 10.1097/00004647-199704000-00009. View

16.

Volkow N, Fowler J, Gatley S, Dewey S, Wang G, Logan J . Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999; 31(1):59-66. DOI: 10.1002/(SICI)1098-2396(199901)31:1<59::AID-SYN8>3.0.CO;2-Y. View

17.

Drevets W, Price J, Kupfer D, Kinahan P, Lopresti B, Holt D . PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology. 2000; 21(6):694-709. DOI: 10.1016/S0893-133X(99)00079-2. View

18.

Scott D, Domino E, Heitzeg M, Koeppe R, Ni L, Guthrie S . Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology. 2006; 32(2):450-7. DOI: 10.1038/sj.npp.1301238. View

19.

Brody A, Mandelkern M, Olmstead R, Allen-Martinez Z, Scheibal D, Abrams A . Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology. 2008; 34(2):282-9. PMC: 2777990. DOI: 10.1038/npp.2008.87. View